Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.

You may also be interested in...



Prexton Therapeutics’ Parkinson’s Assets First to Emerge from Merck KGAA Restructuring

Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.

Deals Of The Week: Merck Serono/Compugen, Lilly/PrimeraDx, Biogen Idec/Isis

With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.

Financings Of The Fortnight Ponders The Potential Of Mapping The Microbiome

Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel